Szarewski, AnneAnneSzarewskiSkinner, S RachelS RachelSkinnerGarland, Suzanne MSuzanne MGarlandRomanowski, BarbaraBarbaraRomanowskiSchwarz, Tino FTino FSchwarzApter, DanDanApterSONG-NAN CHOWPaavonen, JormaJormaPaavonenDel Rosario-Raymundo, M RowenaM RowenaDel Rosario-RaymundoTeixeira, Julio CJulio CTeixeiraDe Carvalho, Newton SNewton SDe CarvalhoCastro-Sanchez, MariaMariaCastro-SanchezCastellsagué, XavierXavierCastellsaguéPoppe, Willy A JWilly A JPoppeDe Sutter, PhilippePhilippeDe SutterHuh, WarnerWarnerHuhChatterjee, ArchanaArchanaChatterjeeTjalma, Wiebren AWiebren ATjalmaAckerman, Ronald TRonald TAckermanMartens, MarkMarkMartensPapp, Kim AKim APappBajo-Arenas, JoseJoseBajo-ArenasHarper, Diane MDiane MHarperTorné, AureliAureliTornéDavid, Marie-PierreMarie-PierreDavidStruyf, FrankFrankStruyfLehtinen, MattiMattiLehtinenDubin, GaryGaryDubin2023-02-172023-02-172013-11-0100221899https://scholars.lib.ntu.edu.tw/handle/123456789/628270Public Health England has reported a decrease of up to 20.8% in new diagnoses of external genital warts (GWs) among women aged <19 years since the national vaccination program with the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine began in 2008. A post hoc analysis of the phase III PATRICIA (PApilloma TRIal against Cancer In young Adults) trial (NCT00122681) was performed to ascertain whether protection against low-risk HPV types was apparent.enHPV; HPV vaccine; genital warts; human papillomavirus[SDGs]SDG3journal article10.1093/infdis/jit360240929072-s2.0-84885393164https://api.elsevier.com/content/abstract/scopus_id/84885393164